Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-08 |
2024-06 |
-0.32 |
N/A |
N/A |
N/A |
2024-05-09 |
2024-03 |
-0.34 |
-0.3 |
0.04 |
11.76% |
2024-03-14 |
2023-12 |
-0.39 |
-0.35 |
0.04 |
10.26% |
2024-03-14 |
2023-12 |
-0.39 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-0.36 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-0.36 |
-0.32 |
0.04 |
11.11% |
Date |
Firm |
Action |
From |
To |
2023-10-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-10-04 |
JonesTrading |
Downgrade |
Buy |
Hold |
2023-09-24 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-10 |
Wells Fargo |
Downgrade |
Overweight |
Equal-Weight |
2023-08-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2020-02-03 |
BELSKY MARC L |
Chief Financial Officer |
17.38K |
Purchase |
2022-03-20 |
BERGER FRANKLIN MILAN |
Director |
890.69K |
Purchase |
2020-02-03 |
ECONOMIDES VASSILIKI NICHOLE |
Officer |
7.57K |
Purchase |
2020-06-10 |
EQUAL TALENT INVESTMENTS, LTD. |
Beneficial Owner of more than 10% of a Class of Security |
6.25M |
Purchase |
2022-11-09 |
FOWLER JOHN FRANKLIN |
Chief Executive Officer |
436.12K |
Conversion of Exercise of derivative security |
2022-01-02 |
KAUFFMAN MICHAEL G |
Director |
63.69K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Suvretta Capital Management, LLC |
7.17M |
17.56M |
9.86% |
2023-06-29 |
Avidity Partners Management, LP |
6.08M |
14.90M |
8.36% |
2023-06-29 |
Orbimed Advisors LLC. |
5.46M |
13.38M |
7.52% |
2023-06-29 |
Blackrock Inc. |
5.09M |
12.47M |
7.00% |
2023-06-29 |
Prosight Management, Lp |
4.65M |
11.40M |
6.40% |
2023-06-29 |
Millennium Management Llc |
3.74M |
9.17M |
5.15% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.88M |
4.60M |
2.58% |
2023-08-30 |
iShares Russell 2000 ETF |
1.60M |
2.39M |
2.21% |
2023-06-29 |
Vanguard Extended Market Index Fund |
764.73K |
1.87M |
1.05% |
2023-08-30 |
iShares Russell 2000 Value ETF |
645.80K |
962.24K |
0.89% |
2023-07-30 |
Fidelity Small Cap Index Fund |
623.69K |
1.40M |
0.86% |
2023-06-29 |
JP Morgan Small Cap Value Fund |
474.23K |
1.16M |
0.65% |